Journal of Clinical Oncology, Vol 15, 3085-3092, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee

SE Krown, MA Testa and J Huang
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

PURPOSE: To prospectively validate the AIDS Clinical Trials Group (ACTG) staging classification for AIDS-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS: Two hundred ninety-four consecutive patients enrolled in eight ACTG therapeutic trials for AIDS-associated KS were staged prospectively according to tumor extent (T), severity of immunosuppression (I), and other systemic human immunodeficiency virus type 1 (HIV-1)-associated illness (S) and were observed for survival. Patients were classified as good risk (subscript 0) or poor risk (subscript 1) for each variable according to published ACTG criteria. Univariate and multivariate analyses were used to evaluate the associations between TIS variables and survival; additional analyses were conducted to improve the predictive value of the staging system. RESULTS: Survival was significantly shorter for patients in the poor- risk category for each of the TIS variables. Respective median survivals for patients in the good- and poor-risk categories were 27 and 15 months for T (P < .001); 40 and 13 months for I (P < .001) when I0 included CD4 counts > or = 200/microL and 22 and 16 months for S (P = .04). Multivariate analysis indicated that severity of immunosuppression gave the most predictive information but also showed that T provided significant additional predictive information in patients whose immune function was least impaired. Refined Cox models using a CD4 count of 150/microL rather than 200/microL to distinguish I0 and I1 yielded a simplified model with better fit to the observed data. CONCLUSION: The ACTG TIS classification predicts survival in patients with AIDS-associated KS; CD4 count and tumor stage provide the most predictive information. However, a lower CD4 count than the one originally proposed provides better discrimination between prognostic groups.

This article has been cited by other articles:

				A Mosam, H P Hurkchand, E Cassol, T Page, S Cassol, U Bodasing, J Aboobaker, H Dawood, G H Friedland, and H M Coovadia Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa Int J STD AIDS, June 1, 2008; 19(6): 400 - 405. [Abstract] [Full Text] [PDF]

				R. F. Little, K. Aleman, P. Kumar, K. M. Wyvill, J. M. Pluda, E. Read-Connole, V. Wang, S. Pittaluga, A. T. Catanzaro, S. M. Steinberg, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma Blood, December 15, 2007; 110(13): 4165 - 4171. [Abstract] [Full Text] [PDF]

				M. R. Goodier, C. M. Mela, A. Steel, B. Gazzard, M. Bower, and F. Gotch NKG2C+ NK Cells Are Enriched in AIDS Patients with Advanced-Stage Kaposi's Sarcoma J. Virol., January 1, 2007; 81(1): 430 - 433. [Abstract] [Full Text] [PDF]

				T. Cooley, D. Henry, M. Tonda, S. Sun, M. O'Connell, and W. Rackoff A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma Oncologist, January 1, 2007; 12(1): 114 - 123. [Abstract] [Full Text] [PDF]

				R. F. Little, J. M. Pluda, K. M. Wyvill, I. R. Rodriguez-Chavez, G. Tosato, A. T. Catanzaro, S. M. Steinberg, and R. Yarchoan Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma Blood, June 15, 2006; 107(12): 4650 - 4657. [Abstract] [Full Text] [PDF]

				M. Bower, M. Nelson, A.M. Young, C. Thirlwell, T. Newsom-Davis, S. Mandalia, T. Dhillon, P. Holmes, B.G. Gazzard, and J. Stebbing Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma J. Clin. Oncol., August 1, 2005; 23(22): 5224 - 5228. [Abstract] [Full Text] [PDF]

				G. Nasti and U. Tirelli Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma (KS): Implications for the Design of Therapeutic Trials in Patients With Advanced Symptomatic KS J. Clin. Oncol., April 1, 2005; 23(10): 2433 - 2433. [Full Text] [PDF]

				S. E. Krown In Reply: J. Clin. Oncol., April 1, 2005; 23(10): 2433 - 2434. [Full Text] [PDF]

				A. Noy, D. T. Scadden, J. Lee, B. J. Dezube, D. Aboulafia, A. Tulpule, S. Walmsley, and P. Gill Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team J. Clin. Oncol., February 10, 2005; 23(5): 990 - 998. [Abstract] [Full Text] [PDF]

				S. E. Krown Highly Active Antiretroviral Therapy in AIDS-Associated Kaposi's Sarcoma: Implications for the Design of Therapeutic Trials in Patients With Advanced, Symptomatic Kaposi's Sarcoma J. Clin. Oncol., February 1, 2004; 22(3): 399 - 402. [Full Text] [PDF]

				J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles, C. Thirlwell, P. Hewitt, M. Nelson, S. Patterson, S. Mandalia, F. Gotch, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations Ann. Onc., November 1, 2003; 14(11): 1660 - 1666. [Abstract] [Full Text] [PDF]

				G. Nasti, R. Talamini, A. Antinori, F. Martellotta, G. Jacchetti, F. Chiodo, G. Ballardini, L. Stoppini, G. Di Perri, M. Mena, et al. AIDS-Related Kaposi's Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals J. Clin. Oncol., August 1, 2003; 21(15): 2876 - 2882. [Abstract] [Full Text] [PDF]

				D. M. Aboulafia, D. Norris, D. Henry, R. J. Grossman, J. Thommes, D. Bundow, R. C. Yocum, and V. Stevens 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma: Results of a Phase 2 Multicenter Clinical Trial Arch Dermatol, February 1, 2003; 139(2): 178 - 186. [Abstract] [Full Text] [PDF]

				S. R. Evans, S. E. Krown, M. A. Testa, T. P. Cooley, and J. H. Von Roenn Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study J. Clin. Oncol., August 1, 2002; 20(15): 3236 - 3241. [Abstract] [Full Text] [PDF]

				R. Tedeschi, M. Enbom, E. Bidoli, A. Linde, P. De Paoli, and J. Dillner Viral Load of Human Herpesvirus 8 in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients with Kaposi's Sarcoma J. Clin. Microbiol., December 1, 2001; 39(12): 4269 - 4273. [Abstract] [Full Text] [PDF]

				J. D. Hillman, A. T. Peng, A. C. Gilliam, and S. C. Remick Treatment of Kaposi Sarcoma With Oral Administration of Shark Cartilage in a Human Herpesvirus 8-Seropositive, Human Immunodeficiency Virus-Seronegative Homosexual Man Arch Dermatol, September 1, 2001; 137(9): 1149 - 1152. [Full Text] [PDF]

				Y. Aoki, R. Yarchoan, K. Wyvill, S.-i. Okamoto, R. F. Little, and G. Tosato Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders Blood, April 1, 2001; 97(7): 2173 - 2176. [Abstract] [Full Text] [PDF]

				A. M. Cattelan, M. L. Calabro, P. Gasperini, S. M. L. Aversa, M. Zanchetta, F. Meneghetti, A. De Rossi, and L. Chieco-Bianchi Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma Regression After Highly Active Antiretroviral Therapy: Biologic Correlates of Clinical Outcome J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 44 - 49. [Abstract] [Full Text] [PDF]

				R. F. Little, K. M. Wyvill, J. M. Pluda, L. Welles, V. Marshall, W. D. Figg, F. M. Newcomb, G. Tosato, E. Feigal, S. M. Steinberg, et al. Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., July 1, 2000; 18(13): 2593 - 2602. [Abstract] [Full Text] [PDF]

				D. M. Aboulafia The Epidemiologic, Pathologic, and Clinical Features of AIDS-Associated Pulmonary Kaposi’s Sarcoma Chest, April 1, 2000; 117(4): 1128 - 1145. [Abstract] [Full Text] [PDF]